RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Authors : Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C
Year : 2017
Journal : JAMA Oncol
Volume : 3
Pages : 227-234

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Authors : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Year : 2017
Journal : Nat Commun
Volume : 8
Pages : 15759

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Authors : Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M
Year : 2017
Journal : Cancer Treat Rev
Volume : 57
Pages : 8-15

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Authors : Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K
Year : 2017
Journal : Mod Pathol
Volume : 30(9)
Pages : 1204-1212

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Authors : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Year : 2017
Journal : Nat Commun
Volume : 8
Pages : 14944

Transcriptomic and genomic features of invasive lobular breast cancer.

Authors : Desmedt C, Zoppoli G, Sotiriou C, Salgado R
Year : 2017
Journal : Semin Cancer Biol
Volume : 44
Pages : 98-105

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

Authors : Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, OMeara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A, Ueno NT, van t Veer LJ, Martens JW, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR
Year : 2017
Journal : Nature
Volume : 543
Pages : 714-718

HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2.

Authors : Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Samira M, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Year : 2017
Journal : Clin Cancer Res
Volume : 23(15)
Pages : 4323-4334

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Authors : Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, Van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S
Year : 2017
Journal : Nat Med
Volume : 23(4)
Pages : 517-525

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Authors : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : 128-135

The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data.

Authors : Bozovic-Spasojevic I, Zardavas D, Brohée S, Ameye L, Fumagalli D, Ades F, de Azambuja E, Bareche Y, Piccart-Gebhart M, Paesmans M, Sotiriou C
Year : 2017
Journal : Clin Cancer Res
Volume : 23(11)
Pages : 2702-2712

MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.

Authors : Denis H, Van Grembergen O, Delatte B, Dedeurwaerder S, Putmans P, Calonne E, Rothé F, Sotiriou C, Fuks F, Deplus R
Year : 2016
Journal : Mol Biosyst
Volume : 12(2)
Pages : 404-13

Characterization of human breast cancer tissues by infrared imaging.

Authors : Verdonck M, Denayer A, Delvaux B, Garaud S, de Wind R, Desmedt C, Sotiriou C, Willard-Gallo K, Goormaghtigh E
Year : 2016
Journal : Analyst
Volume : 141(2)
Pages : 606-19

The topography of mutational processes in breast cancer genomes.

Authors : Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim HY, Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, Van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Sale J, Rada C, Stratton MR, Birney E, Nik-Zainal S
Year : 2016
Journal : Nat Commun
Volume : 7
Pages : 11383

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Authors : Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart-Gebhart M, Dowsett M, Michiels S, Leyland-Jones B
Year : 2016
Journal : JAMA Oncol
Volume : 2(8)
Pages : 1040-7

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Authors : Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, OMeara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Veer LV, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, Van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR
Year : 2016
Journal : Nature
Volume : 534(7605)
Pages : 47-54

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

Authors : Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C
Year : 2016
Journal : J Clin Oncol
Volume : 34(16)
Pages : 1872-81

The current use and attitudes towards tumor genome sequencing in breast cancer.

Authors : Gingras I, Sonnenblick A, de Azambuja E, Paesmans M, Delaloge S, Aftimos P, Piccart-Gebhart M, Sotiriou C, Ignatiadis M, Azim HA Jr
Year : 2016
Journal : Sci Rep
Volume : 6
Pages : 22517

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Authors : Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Loi S, Smyth MJ
Year : 2016
Journal : Cancer Res
Volume : 76
Pages : 264-74

Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors : Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S
Year : 2016
Journal : Nat Rev Clin Oncol
Volume : 13(4)
Pages : 228-41